Is MELA a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,151 people get MELA articles and Market Currents by email alert.

Get email alerts on MELA »

HEADLINES:

Detecting Investment Potential In Medical Diagnostics Companies
Chemistfrog • Tue, May 7 • 5 Comments
MELA Sciences' CEO Hosts Analyst Meeting (Transcript)
Mon, May 6
MELA Sciences, Inc. Rings NASDAQ Opening Bell With Leading Dermatologists To Raise Awareness For Melanoma Detection And Prevention

PR Newswire (May 6, 2013)
MELA Sciences' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 1 • 1 Comment
MELA Sciences Announces First Quarter 2013 Financial Results

GlobeNewswire (Apr 30, 2013)
MELA Sciences, Inc. Partners With Dermatologists Nationwide To Promote Skin Cancer Awareness

PR Newswire (Apr 23, 2013)
MELA Sciences to Host Investor Meeting in Conjunction With Melanoma Monday on May 6th 2013 in New York

GlobeNewswire (Apr 18, 2013)
MELA Sciences to Participate in Upcoming 12th Annual Needham Healthcare Conference

GlobeNewswire (Apr 15, 2013)
MELA Sciences to Release First Quarter 2013 Financial Results and Host Conference Call on Tuesday, April 30, 2013

GlobeNewswire (Apr 10, 2013)
When Will Mela Science's Price Become Sustainable?
Derek Chipman • Thu, Mar 21 • 7 Comments
2 Cancer Stocks Ready To Rally
BuySellShort • Thu, Mar 21 • 20 Comments
Investing In The Medical Diagnostic Device Sector In 2013
Emerging Growth • Thu, Mar 21 • 1 Comment
MELA Sciences, Inc. Presents New Data That Reinforces The Importance Of MelaFind® As A Diagnostic Tool At AAD Meeting

PR Newswire (Mar 18, 2013)
MELA Sciences Management Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Mar 5
MELA Sciences Announces Fourth Quarter and Year End 2012 Financial Results

GlobeNewswire (Mar 5, 2013)
Epidemic Increases In Melanoma Rates Three Of Four Americans Surveyed Have Never Had Skin Cancer Examination

PR Newswire (Feb 21, 2013)
MELA Sciences Prices Public Offering of Common Stock; Termination of At the Market (ATM) Equity Offering Program; and Execution of Term Sheet for Debt Financing

GlobeNewswire (Feb 12, 2013)
Small Pharma Watch List: Week Of February 11th, 2013
Chemistfrog • Mon, Feb 11 • 4 Comments
MELA Sciences to Release Fourth Quarter and Year End 2012 Financial Results and Host Conference Call on Tuesday, March 5, 2013

GlobeNewswire (Feb 4, 2013)
MELA Sciences to Present at Upcoming Investor Conferences

GlobeNewswire (Jan 28, 2013)

To learn more about Seeking Alpha Pro, click here.

When Will Mela Science's Price Become Sustainable?
Derek Chipman • Thu, Mar 21 • 7 Comments
In This Put-Up-Or-Shut-Up Year, MELA Sciences Should Succeed With Its Launch Of MelaFind
Smith On Stocks • Thu, Jan 24 • 31 Comments
MELA Sciences: A Hidden Gem That Could Bring A Stock Price Double This Year
Scott Matusow • Tue, Mar 6, 2012 • 29 Comments
Trading MELA Sciences' Pending FDA Decision
Tony Pelz • Thu, Nov 11, 2010 • 6 Comments
Why Bears Expect MELA to Plunge
optionMONSTER • Thu, Nov 11, 2010 • 17 Comments
Electro-Optical Sciences: A Speculative Stock with Great Potential
Cabot • Tue, Jul 7, 2009 • 9 Comments
Summary of Electro-Optical Sciences' Corporate Presentation
Mike Havrilla • Tue, Mar 24, 2009 • 1 Comment
Electro-Optical Sciences: Positive Results for MelaFind
Mike Havrilla • Tue, Mar 17, 2009 • 6 Comments
Electro-Optical Sciences' Shares Up on Trial Results Announcement
Douglas Cress • Mon, Jan 5, 2009 • 1 Comment
Electro Optical Sciences: CEO Explains Melanoma Detection Device
Douglas Cress • Mon, Dec 3, 2007 • 1 Comment
Electro-Optical Raises $11.5 Million For Development Of Melanoma Diagnosis Device
Sara Calabro • Thu, Aug 2, 2007
Electro-Optical Sciences Seeks Partners for Melanoma Detection Device
Douglas Cress • Wed, Jun 20, 2007

Detecting Investment Potential In Medical Diagnostics Companies
Chemistfrog • Tue, May 7 • 5 Comments
2 Cancer Stocks Ready To Rally
BuySellShort • Thu, Mar 21 • 20 Comments
Investing In The Medical Diagnostic Device Sector In 2013
Emerging Growth • Thu, Mar 21 • 1 Comment
Small Pharma Watch List: Week Of February 11th, 2013
Chemistfrog • Mon, Feb 11 • 4 Comments
With Tax-Loss Selling Over, These Below $7 Medical Device Stocks Are Heating Up
Trade In Mexico • Thu, Jan 10 • 9 Comments
These Neglected $1 Stocks Could Offer Major Upside In A Short Squeeze Or Takeover
Trade In Mexico • Wed, Jan 9 • 16 Comments
5 Healthcare Companies With Significant Recent Insider Buying (Part IV)
Markus Aarnio • Wed, Nov 14, 2012
This Bio-Pharma Is Being Hyped While Insiders Are Dumping Shares
Joe Springer • Fri, Aug 24, 2012 • 79 Comments
7 Fast Growth Healthcare Stocks With Generous Reserves
ZetaKap • Tue, Jul 31, 2012 • 1 Comment
6 Healthcare Stocks Positioned For High Growth
ZetaKap • Fri, Jul 20, 2012 • 1 Comment
12 High-Growth Small Caps Under $5 Being Bought Up By Hedge Funds
Kapitall • Fri, Apr 27, 2012 • 3 Comments
6 High-Growth Stocks Under $5 With Bullish Short Trends
Kapitall • Tue, Feb 7, 2012 • 1 Comment
BioMimetic Therapeutics: The FDA Gives A Smudged Map For The Minefields
Stephen Simpson • Thu, Jan 5, 2012 • 1 Comment
Analyzing Wednesday's Noteworthy Insider Buys And Sells
GuruFundPicks • Thu, Dec 22, 2011
Verisante Technology: The Future Of Cancer Detection
Michael Anderson • Mon, Nov 21, 2011 • 33 Comments
4 Rallying Small-Cap Stocks With Sharp Increases In Shares Shorted
Kapitall • Fri, Oct 14, 2011
5 Micro-Cap Stocks Dragged Down By Extreme Pessimism
Kapitall • Thu, Oct 6, 2011 • 3 Comments
Buy And Sell Ideas Based On Monday's Top Gainers
GuruFundPicks • Tue, Sep 27, 2011
Build My Portfolio: Taking Some Of This Poker Player's Chips Off The Table
Robert Balopole • Thu, Aug 25, 2011 • 22 Comments
5 Stocks on the Move From Wednesday
Alex Shadunsky • Thu, Aug 18, 2011

MELA Sciences' CEO Hosts Analyst Meeting (Transcript)
Mon, May 6
MELA Sciences' CEO Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 1 • 1 Comment
MELA Sciences Management Discusses Q4 2012 Results - Earnings Call Transcript
Tue, Mar 5
MELA Sciences Management Discusses Q3 2012 Results - Earnings Call Transcript
Wed, Nov 7, 2012
MELA Sciences' CEO Discusses Q2 2012 Results - Earnings Call Transcript
Wed, Aug 8, 2012 • 1 Comment

MELA Sciences, Inc. Rings NASDAQ Opening Bell With Leading Dermatologists To Raise Awareness For Melanoma Detection And Prevention

PR Newswire (May 6, 2013)
MELA Sciences Announces First Quarter 2013 Financial Results

GlobeNewswire (Apr 30, 2013)
MELA Sciences, Inc. Partners With Dermatologists Nationwide To Promote Skin Cancer Awareness

PR Newswire (Apr 23, 2013)
MELA Sciences to Host Investor Meeting in Conjunction With Melanoma Monday on May 6th 2013 in New York

GlobeNewswire (Apr 18, 2013)
MELA Sciences to Participate in Upcoming 12th Annual Needham Healthcare Conference

GlobeNewswire (Apr 15, 2013)
MELA Sciences to Release First Quarter 2013 Financial Results and Host Conference Call on Tuesday, April 30, 2013

GlobeNewswire (Apr 10, 2013)
MELA Sciences, Inc. Presents New Data That Reinforces The Importance Of MelaFind® As A Diagnostic Tool At AAD Meeting

PR Newswire (Mar 18, 2013)
MELA Sciences Announces Fourth Quarter and Year End 2012 Financial Results

GlobeNewswire (Mar 5, 2013)
Epidemic Increases In Melanoma Rates Three Of Four Americans Surveyed Have Never Had Skin Cancer Examination

PR Newswire (Feb 21, 2013)
Movers & Shakers: Tuesday’s biggest gaining and declining stocks

at MarketWatch.com (Feb 12, 2013)
MELA Sciences Prices Public Offering of Common Stock; Termination of At the Market (ATM) Equity Offering Program; and Execution of Term Sheet for Debt Financing

GlobeNewswire (Feb 12, 2013)
MELA Sciences to Release Fourth Quarter and Year End 2012 Financial Results and Host Conference Call on Tuesday, March 5, 2013

GlobeNewswire (Feb 4, 2013)
MELA Sciences to Present at Upcoming Investor Conferences

GlobeNewswire (Jan 28, 2013)
MELA Sciences to Participate in Upcoming 15th Annual Needham Growth Conference

PR Newswire (Jan 4, 2013)
MELA Sciences Names Rpr Marketing Communications as its New Agency of Record

PR Newswire (Jan 3, 2013)
MELA Sciences to Participate in Upcoming Stephens Fall Investor Conference

GlobeNewswire (Nov 9, 2012)
MELA Sciences Announces Third Quarter 2012 Financial Results

GlobeNewswire (Nov 7, 2012)
MelaFind Chosen as One of Top 10 Medical Innovations for 2013 by Cleveland Clinic

GlobeNewswire (Nov 5, 2012)
MELA Sciences to Release Third Quarter Financial Results and Host Conference Call on Wednesday, November 7, 2012

GlobeNewswire (Oct 24, 2012)
MELA Sciences Announces Second Quarter 2012 Financial Results

Marketwire (Aug 7, 2012)

MELA vs. ETF Alternatives

Company Description

Sector: Healthcare

Industry: Medical Instruments & Supplies

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 1, 3:46 PM Mela Sciences (MELA -10.6%) takes a hit today after its Q1 revenue misses by a huge margin despite a nearly 12-fold increase over year-ago levels. Revenue for the three months ended March 31 totaled $144,100, up from $11,250 during the same quarter last year but still lagging the analyst consensus by more than 76%, as a sizeable chunk of the quarters revenue from Melafind sales were deferred. 3 Comments [Healthcare, Earnings, On the Move]
Wednesday, May 1, 4:42 AM MELA Sciences (MELA): Q1 EPS of -$0.17 beats by $0.01. Revenue of $144K misses by $466K. (PR) 1 Comment [Earnings, Breaking News, Healthcare]
Wednesday, March 6, 3:18 PM Mela Sciences (MELA -17%) reverses yesterday's post-session gains and sinks on a disappointing Q4. Higher marketing expenses, coupled with an increase in costs associated with installing its Melafinds systems in medical offices, all conspired to pressure margins. Comment! [Healthcare, Earnings, On the Move]
Tuesday, March 5, 6:47 PM More on Mela Sciences (MELA): Q4 comes in line with estimates. Net loss for quarter was $6.1M, or $0.19 per diluted share, compared to a net loss of $4.5M, or $0.17 per diluted share for Q411. The higher net losses can be attributed to greater SG&A costs, and an increase in direct costs associated with the placement of MelaFind systems in dermatologists' offices. Total revenues were boosted by increased installation of its MelaFind, with 20 additional user agreements signed in Q4. Shares +4.2% AH. Comment! [Healthcare, Earnings, On the Move]
Tuesday, March 5, 4:29 PM MELA Sciences (MELA): Q4 EPS of -$0.19 in-line. Revenue of $122.3K. Shares -3.4% AH. (PR) 1 Comment [Earnings, Breaking News, Healthcare]
Tuesday, February 12, 4:06 PM MELA Sciences (MELA -13%) finishes lower today after pricing its 6.1M share public offering at $1.30 per share, a 23% discount to yesterdays close. The company plans to use the funds for its commercial launch of MelaFind. Comment! [Healthcare, On the Move]
Tuesday, February 12, 12:45 PM Midday top 10 gainers: XRSC +35%. RSOL +31%. STEM +24%. ZIOP +19%. AVP +19%. AMRI +18%. OSBC +16%. DQ +14%. MAS +13%. GILT +12%.
Midday top 10 losers: KVHI -11%. ATAI -11%. LVLT -11%. CLSN -10%. RBPAA -10%. MELA -10%. RVLT -10%. CBMX -10%. QLYS -9%. APRI -8%. Comment! [On the Move]
Tuesday, February 12, 9:31 AM MELA Sciences (MELA) swoons 7.7% to $1.56 after the medical-devices company prices a stock-offering of 6.1M shares at $1.30 each, well below the firm's close yesterday of $1.69. MELA plans to use the net proceeds of $7.3M for the launch of its MelaFind skin-cancer product in the U.S. and EU, and for R&D. MELA also says it's signed a term sheet with a VC lender for a 3.5 year loan of up to $10M at interest of 10.45%/year. (PR) Comment! [On the Move, Healthcare]
Tuesday, February 12, 9:10 AM Premarket gainers: STEM +30%. ZIOP +14%. KORS +12%. MAS +8%. AVP +7%. HERO +7%. BCS +7%. GY +6%. OPXA +6%. GTE +5%.
Losers: MELA -17%. ORIG -5%. WNS -5%.
Comment! [On the Move]
Thursday, January 17, 12:58 PM Mela Sciences (MELA -7.6%) trades lower today after the company gave its presentation at Needham's Growh Conference yesterday, saying it plans to restructure its manufacturing operations this year to "significantly reduce manufacturing costs" of MelaFind, its hand-held device identifying possible melanoma, in an effort to relieve pressure on its margins. 2 Comments [Healthcare, On the Move]
Thursday, January 17, 12:53 PM Midday top 10 gainers: NEWL +55%. KSWS +48%. SSE +44%. HMNY +21%. CALI +25%. GV +18%. FSI +14%. SHIP +14%. HILL +13%. NLS +13%.
Midday top 10 Losers: HOTR -17%. AMS -13%. PWER -8%. MY -8%. FET -7%. SZYM -8%. CLSN -8%. LEAP -7%. FOLD -7%. MELA -7%. Comment! [On the Move]
Thursday, February 23, 2012, 9:00 AM Premarket gainers: VVUS +107%. OREX +22%. ARNA +15%. SHLD +13%. MELA +7%. QCOR +6%. RIG +5%. RBS +5%. RND +5%. KYG +4%. XIN +4%. DNDN +3%. THLD +3%. GOLD +3%. MTG +3%.
Losers: BNK -14%. PPO -11%. TSL -7%. BRD -7%. SLT -5%. HPQ -4%. YGE -4%. SINA -4%. FSLR -4%. KSS -3%. PSEC -3%. CSIQ -3%. ALJ -3%. 1 Comment [On the Move]
Friday, December 16, 2011, 10:59 AM MELA Sciences (MELA -11.8%) says its 5M share secondary placement priced at $3.25, an 18% discount to Thursday's close. The medical-device maker is seeking to raise funds to bring MelaFind, its tool for melanoma skin cancer detection, to market. Comment! [Healthcare, On the Move]
Monday, November 7, 2011, 3:39 PM Mela Sciences (MELA +11.6%) rises after an article in Barron's over the weekend cites a Needham analyst who says the recent FDA approval of MelaFind could push the stock as high as $20 over the next year. 1 Comment [Healthcare, On the Move]
Wednesday, November 2, 2011, 9:00 AM Premarket gainers: HGG +15%. MELA +11%. GRMN +10%. MGIC +9%. MA +7%. JDSU +6%. AUO +5%. CHU +5%. EXEL +5%. RENN +5%. RDN +5%. NBG +4%. HAL +4%. AKS +4%. BAC +4%. LNG +4%. PCS +3%. MS +3%. FCX +3%. SIRI +3%. S +3%. C +3%. AA +3%.
Losers: DMND -16%. OPEN -13%. VG -12%. HGSI -7%. BDX -6%. LYG -5%. CTSH -4%. Comment! [On the Move]
Wednesday, November 2, 2011, 8:52 AM Mela Sciences (MELA) +9.5% - but down from +19% - after the FDA OKs the firm's MelaFind device for detecting melanoma. The approval follows a 2.5-year attempt and is expected to allow doctors to signficantly reduce the number of invasive biopsies. 1 Comment [Healthcare]

arca3x
any thoughts on $MELA?
Mar 29, 2:42 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

jtimrick
Actually Melafind which is the main product being offered by $MELA was approved on 11-1-11. Here is a link: http://1.usa.gov/WnjnSR
Mar 13, 11:22 AM
Reply (2)

• !Report Abuse
View all 2 replies
techwonk: It's a pre-market approval (PMA) see the co. website. Not sure why it still shows as that, they seem to be selling now.
Mar 28, 6:43 PM
• !Report Abuse
techwonk: http://seekingalpha.com/a/o971 Here's a Jan. Editor's pick with more pro and con in the comments.
Mar 28, 6:44 PM
• !Report Abuse
Add a reply...

140 characters

jtimrick
$MELA has been sliding, is now the time to buy? Close to 52 week low, could have a strong upside.
Mar 12, 5:47 PM
Reply (4)

• !Report Abuse
View all 4 replies
techwonk: Well, I'm wrong on this, they got a PMA (preliminary) tho I don't see a final sign off. New article on SA : http://seekingalpha.com/a/rpiv
Mar 23, 6:49 PM
• !Report Abuse
techwonk: http://yhoo.it/ZWQMmz You might also want to read this one.
Mar 23, 6:52 PM
• !Report Abuse
Add a reply...

140 characters

joe kelly
$MELA Sadly foul language is frowned upon at SA. That's the only way to describe this jive turkey!
Feb 25, 10:53 AM
Reply (5)

• !Report Abuse
View all 5 replies
joe kelly: This is what i get when I have too much cash in my portfolio. Off to 7-11 for smokes and TP to wipe the turd that is MELA away.
Feb 25, 11:10 AM
• !Report Abuse
Perkins Cove: Ok, you got it.......haha
Feb 25, 11:11 AM
• !Report Abuse
Add a reply...

140 characters

jrusso9722
$MELA has to show a strong 4Q 2012, or it's a long fall IMHO.
12/27/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Derek Chipman
$MELA - a medical equipment company long sought by hedge funds, will hedge funds buy this speculative $2 play in FY 2013 or steer clear?
12/25/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
7 Fast Growth Healthcare Stocks With Generous Reserves http://bit.ly/QdI4wS $SRDX $CPIX $IMGN $MELA $QLTI $VVUS $CORT @ZetaKap
7/31/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
6 Healthcare Stocks Positioned For High Growth http://bit.ly/OMUbMU $CORT $ISIS $MELA $CYBX $PACB $EBS @ZetaKap
7/20/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

pat50
Hope MELA product will eliminate some biopsies or allow remove then biopsy_docs biopsy then remove cancer 2 months later now
5/4/12
Reply (1)

• !Report Abuse
View all 1 replies
jrusso9722: Expecting a healthier 2nd Quarter sales report.
7/12/12
• !Report Abuse
Add a reply...

140 characters

jrusso9722
There should be an information release, by MELA, in earl April, concluding first quarter, 2012, as well as more frequent news.
3/15/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

jtimrick
Actually Melafind which is the main product being offered by $MELA was approved on 11-1-11. Here is a link: http://1.usa.gov/WnjnSR
Mar 13, 11:22 AM
Reply (2)

• !Report Abuse
View all 2 replies
techwonk: It's a pre-market approval (PMA) see the co. website. Not sure why it still shows as that, they seem to be selling now.
Mar 28, 6:43 PM
• !Report Abuse
techwonk: http://seekingalpha.com/a/o971 Here's a Jan. Editor's pick with more pro and con in the comments.
Mar 28, 6:44 PM
• !Report Abuse
Add a reply...

140 characters

jtimrick
$MELA has been sliding, is now the time to buy? Close to 52 week low, could have a strong upside.
Mar 12, 5:47 PM
Reply (4)

• !Report Abuse
View all 4 replies
techwonk: Well, I'm wrong on this, they got a PMA (preliminary) tho I don't see a final sign off. New article on SA : http://seekingalpha.com/a/rpiv
Mar 23, 6:49 PM
• !Report Abuse
techwonk: http://yhoo.it/ZWQMmz You might also want to read this one.
Mar 23, 6:52 PM
• !Report Abuse
Add a reply...

140 characters

joe kelly
$MELA Sadly foul language is frowned upon at SA. That's the only way to describe this jive turkey!
Feb 25, 10:53 AM
Reply (5)

• !Report Abuse
View all 5 replies
joe kelly: This is what i get when I have too much cash in my portfolio. Off to 7-11 for smokes and TP to wipe the turd that is MELA away.
Feb 25, 11:10 AM
• !Report Abuse
Perkins Cove: Ok, you got it.......haha
Feb 25, 11:11 AM
• !Report Abuse
Add a reply...

140 characters

pat50
Hope MELA product will eliminate some biopsies or allow remove then biopsy_docs biopsy then remove cancer 2 months later now
5/4/12
Reply (1)

• !Report Abuse
View all 1 replies
jrusso9722: Expecting a healthier 2nd Quarter sales report.
7/12/12
• !Report Abuse
Add a reply...

140 characters

Ryan Mallory
3/2 Video Watchlist SCEI MELA RSYS MMR GA ATML ARIA SAH UCTT ALNY ACHN BTU REXX INAP ANW CNX ALSK http://www.bit.ly/A4YhPa
3/2/12
Reply (7)

• !Report Abuse
View all 7 replies
Ryan Mallory: sure will
3/6/12
• !Report Abuse
phemale60: has some useful information but I guess they are also trying to push their Biotech Supertrader program. Love their "quote of the day"!
3/6/12
• !Report Abuse
Add a reply...

140 characters

lfpdinc
MELA is not backing down
1/31/12
Reply (2)

• !Report Abuse
View all 2 replies
Ricardo Espinosa: It´s a really strong stock, you won´t beleive how much people in latin america spend on stupid things they think they need.
1/31/12
• !Report Abuse
lfpdinc: *was not
1/31/12
• !Report Abuse
Add a reply...

140 characters

lfpdinc
MELA, one of my dogs is barking today...don't know why though
1/30/12
Reply (2)

• !Report Abuse
View all 2 replies
jelinvest: I believe that in the near term MELA is poised to rise. MELA has just begun its sales effort. Most Analysts still rate it Buy to Strg buy.
1/30/12
• !Report Abuse
lfpdinc: that action today.....need more of that
1/30/12
• !Report Abuse
Add a reply...

140 characters

jrusso9722
Mela Sciences has announced this morning, 11-2-11, that the FDA has approved MelaFind. MELA
11/2/11
Reply (1)

• !Report Abuse
View all 1 replies
tenax: huge story for MELA investors. here's the goods: http://yhoo.it/tGOL4O
11/2/11
• !Report Abuse
Add a reply...

140 characters

pat50
Amazing not a single word on CNBC, analyst comment, ect on MELA's FDA approval or EU approval. Market cap of 100mil is still cheap.
9/27/11
Reply (2)

• !Report Abuse
View all 2 replies
pat50: This company really needs some market coverage-all the bears who are short rule the chatter.
9/27/11
• !Report Abuse
jrusso9722: Hi pat50, Yes, I agree. Saving lives is the issue. Shorters will eat their shorts. MelaFind will save lives---non invasively.
10/3/11
• !Report Abuse
Add a reply...

140 characters

MELA MELA Sciences, Inc.

MELA

MELA Sciences, Inc.